Albert Bourla, Pfizer CEO (Evan Vucci, AP Images)

Covid-19 roundup: Pfiz­er sub­mits EUA for Omi­cron-tar­get­ed boost­er; No­vavax EUA ex­pands to teens

The Omi­cron-tar­get­ed boost­ers are com­ing. Al­most 250 days since Omi­cron be­came the dom­i­nant vari­ant in the US, Pfiz­er and BioN­Tech on Mon­day of­fi­cial­ly an­nounced that they’ve re­quest­ed an EUA for their boost­er dose of an Omi­cron BA.4/BA.5-adapt­ed bi­va­lent vac­cine for those 12 and old­er.

The ap­pli­ca­tion’s sub­mis­sion comes as BioN­Tech said ear­li­er this month that it ex­pects to be­gin de­liv­er­ing Omi­cron-adapt­ed vac­cines as ear­ly as Oc­to­ber, sub­ject to reg­u­la­to­ry ap­proval.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.